Journal of Functional Foods (Jul 2022)

Regulation of Th2 responses by Lactococcus lactis subsp. cremoris YRC3780 alleviates DNCB-induced atopic dermatitis in the mouse model

  • Rong Wang,
  • Haruyo Nakajima-Adachi,
  • Yimei Wang,
  • Yingyu Zhou,
  • Wenting Gu,
  • Erika Hiraide,
  • Mamiko Morinaga,
  • Ryogo Nakagawa,
  • Shotaro Nakamura,
  • Tomohiro Takano,
  • Xuyang Li,
  • Mayumi Saeki,
  • Osamu Kaminuma,
  • Takachika Hiroi,
  • Kenji Uchida,
  • Hidemasa Motoshima,
  • Masaru Tanokura,
  • Takuya Miyakawa,
  • Satoshi Hachimura

Journal volume & issue
Vol. 94
p. 105091

Abstract

Read online

Lactococcus lactis subsp. cremoris YRC3780 (L. cremoris YRC3780) was isolated from kefir, and anti-allergic effects have been confirmed in humans. The mechanisms by which L. cremoris YRC3780 affects the Th1/Th2 balance in mice were investigated in vitro, focusing on the intestinal immune response. Simultaneously, a 2,4-dinitrochlorobenzene-induced atopic dermatitis mouse model was used to evaluate the symptom improvement effect of oral administration of L. cremoris YRC3780. The results showed that L. cremoris YRC3780 enhanced IFN-γ and IL-12 production and inhibited IL-4 production from CD4+ T cells in the presence of various types of immune cells. Oral administration of L. cremoris YRC3780 attenuated serum total IgE (p < 0.05) and decreased ear thickness (p < 0.05) in the atopic dermatitis model. The examination of cytokine expression suggested that L. cremoris YRC3780 improved AD-like symptoms by inhibiting IL-4 gene expression from Peyer's patches CD4+ T cells (p < 0.01) and IL-33 gene expression (p < 0.05) in the draining lymph nodes.

Keywords